Coya Therapeutics Inc (COYA) Unusual Options Activity Today

Checking COYA unusual options activity helps you spot when traders are making outsized bets on Coya Therapeutics Inc before the broader market catches on. Coya Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor COYA unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching COYA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking COYA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and COYA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.

It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Catalysts rarely arrive without a footprint, and COYA unusual options activity is often where that footprint shows up first. Our scanner tracks Coya Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at COYA unusual options volume on the call side or chasing put sweeps, Coya Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.